

CVP Update



The following is reprinted with permission from the Connecticut State Medical Society
CONNECTICUT MEDICINE JANUARY 2017 VOLUME 81 NUMBER 1 pg. 46-47

If There Were a Vaccine Against Cancer...

Commissioner Raul Pino, M.D., M.P.H.
Connecticut Department of Public Health

By now we have likely all heard, despite an excellent efficacy and safety record, that the human papillomavirus (HPV) vaccine might be the most underutilized vaccine in the US. While vaccination rates continue to improve for the other adolescent vaccines, HPV rates have remained mostly flat (1). National estimates for administration of the first dose of HPV vaccine compared with those for other adolescent vaccines are over 20 percentage points lower. There are several reasons for this, including parental perception of low risk of infection, concerns for vaccine safety, effect on sexual behavior, vaccine cost, and irregular preventive care (2). So where do we go from here?

As it turns out, what we say, and how we say it, matters. Recent evidence points to the lack of a clear, strong recommendation for HPV vaccine for adolescents at age 11 or 12 years as one reason for its failure to launch (3,4). Public health shares the blame for such reticence. The vaccine was recommended by the Advisory Committee on Immunization Practices (ACIP) nearly ten years ago for females, and five years ago for males. It is time that the Department of Public Health pursues legislation to make the vaccination mandatory for adolescents starting in the seventh grade. A proposal to require the HPV vaccine has been included with the Department's legislative package for the upcoming session. We must work together to ensure that Connecticut's children do not grow up to become victims of preventable cancers.

I need your help. I ask that you, our partners in protecting the public's health, give a clear, concise recommendation for HPV vaccine. The healthcare provider recommendation is the single best predictor of vaccination. Recent studies show that a patient who receives a provider recommendation is four to five times more likely to receive the HPV vaccine (3,4). In addition, research shows that simply changing the words used to introduce HPV vaccine makes a tremendous difference in vaccine acceptance. The following are a few suggestions from the National HPV Roundtable to start the vaccine discussion with all 11- and 12-year-olds and their parents:

“Now that your child is 11, he/she is due for three vaccines. These will help protect him/her from meningitis, HPV cancers, and pertussis. We’ll give those shots at the end of the visit.”

“Your preteen needs three vaccines today to protect against meningitis, HPV cancers, and pertussis.”

By confidently stating the child is due for three vaccines, and by putting the HPV vaccine in the middle of the recommendation (instead of at the end as an afterthought), parents perceive that it’s a normal, recommended vaccine rather than a controversial or optional one. Research has shown that this approach significantly increases the likelihood of vaccination (3,4). The Centers for Disease Control and Prevention’s (CDC) *Tips and Time-savers for Talking with Parents about HPV Vaccine* is a resource that offers language you can use to address parental concerns (and is available in English and Spanish).

Thankfully, we are also getting some reinforcement with this effort. The ACIP and the CDC now recommend only two doses of HPV vaccine for adolescents who begin the vaccination series before age 15.

HPV vaccine recommendations for target age groups remain the same as before. Routine HPV vaccination is recommended at age 11 or 12 years. The vaccination series can be started at age nine years. Vaccination is recommended through age 26 for females and through age 21 for males not vaccinated previously. Males aged 22 through 26 years may be vaccinated; vaccination is recommended through age 26 years for males in some special populations and those with immunocompromised conditions.

According to CDC, providers should:

- Schedule patients starting the vaccination series before age 15 to receive their second dose of HPV vaccine six to 12 months after receiving the first dose.
- Continue to provide teens and young adults who start the series at ages 15 through 26 years three doses of HPV vaccine.

While it might take some time to incorporate the new dosing recommendation into practice, a two-dose series means it will be easier to protect preteens from HPV-related disease and cancers. To take advantage of the two-dose schedule, providers should review a patient’s vaccination history carefully. If a patient has already received the first dose of HPV vaccine before age 15 and received a second dose of vaccine at least five months later, the patient is considered adequately vaccinated and does not need a third dose. Frequently asked questions about the new two-dose schedule can be found on the DPH web site.

So now, I close with a challenge. Have we done everything we can do to avert these preventable cancers, or can we do more? I believe we can and should do more so we don’t fail our children and grandchildren. Now that there is a vaccine against some types of cancers, are we debating if our children should get vaccinated? Are we imposing our own views and beliefs on our patients?

Recommended number of doses and dosing schedule for HPV vaccine

<i>Recommended number of doses</i>	<i>Recommended dosing schedule</i>	<i>Population</i>
2	0, 6 – 12 months	Persons initiating vaccination at ages nine through 14 years, except immunocompromised persons
3	0, 1 – 2 months, 6 months	Persons initiating vaccination at ages 15 through 26 years, and immunocompromised persons initiating vaccination at ages nine through 26 years

REFERENCES

1. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years — United States, 2015. *MMWR*. 2016;65(33):850–8.
2. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. *JAMA Pediatr*. 2014;168(1):76–82.
3. Health care provider recommendation virus vaccination, and race/ethnicity in the U.S. National Immunization Survey. *Am J Public Health*. 2013;103(1):164–9.
4. Factors associated with human papillomavirus vaccine-series initiation and healthcare provider recommendation in U.S. adolescent females: 2007 National Survey of Children’s Health. *Vaccine*. 2012;30(20):3112–8.

For additional questions or information on immunizations, please contact the Connecticut Vaccine Program at (860) 509-7929.

HPV Webinars for CME

Connecticut Chapter of the American Academy of Pediatrics and the DPH State Immunization Program Webinar: You Are The Key: Getting into the Routine of Recommending Cancer Prevention in Connecticut
Thursday, May 18th, 12:10 – 1:00PM <http://ct-aap.org/2017>

HPV Immunization: Ensuring Your Patients Do Not Slip through the Cracks
http://www.healio.com/pediatrics/education-lab/2016/12_december/hpv-immunization/cme-information



HPV Vaccination Partner Toolkit



Use the Establishing Partner Networks section of the [HPV Vaccination Partner Toolkit](#) to discover how engaging local partners can increase public awareness and support for HPV vaccination, as well as promote strong collaborations to improve coverage rates. Specifically, you can:

- Find the partner organizations already working on HPV vaccination initiatives in your state with the [HPV Vaccination Initiative Contact Map](#).
- Understand the process for establishing state or local HPV vaccination roundtables or coalitions, based on best practices and real-life experiences.
- Learn from [HPV Champions](#) who have successfully improved coverage, in Partner, Program, and Provider Spotlights.
- Discover the resources, tools, and survivor testimonials developed by the American Cancer Society, and learn more about the [National HPV Vaccination Roundtable](#).
- Gather clinician-specific resources for improving practice coverage rates with the AAP HPV Champion Toolkit.
- Help clinicians make effective recommendations and improve office practices by sharing [Tips for Talking to Parents about HPV Vaccine](#) and the [Top 10 Ways to Improve HPV Vaccination Rates in Your Practice](#).
- [Syndicate](#) CDC's HPV vaccination content for parents to your website to keep your website up-to-

The Connecticut Vaccine Program ensures all children in the state receive the vaccinations they need to stay healthy. For more information, visit us at www.ct.gov/dph/cvp or contact us at (860) 509-7929 or dph.immunizations@ct.gov. To sign up for E-Alerts, click on the "Sign up for E-Alerts" icon on the left-hand side of any Department of Public Health web page. Register and submit the form. Check the box to receive updates from "**Connecticut Vaccine Program: News, Updates, Alerts**". To Get Started Click on <http://www.ct.gov/dph/guestaccount/login.asp>.

Connecticut Doctor Receives *CDC's Childhood Immunization Champion Award*



Dr. Linda Niccolai with award nominators Jennifer Hall, New Haven IAP, Christine DePierro-Gacek, West Haven IAP

The *CDC Childhood Immunization Champion Award* is an annual award given jointly by the [CDC Foundation](#) and CDC to recognize individuals who make a significant contribution toward improving public health through their work in childhood immunization.

Nominations are based on leadership, collaboration, innovation, and advocacy. “Immunization champions and the work they do are essential to protecting our children, schools, and communities from serious disease. “We could not achieve our goal of protecting children without those committed individuals who promote immunizations at the state and local levels.

Dr. Linda M. Niccolai has been named *CDC Childhood Immunization Champion* for her outstanding efforts to promote childhood immunization in the state of Connecticut.

Dr. Niccolai's commitment to childhood immunizations is demonstrated through her work in both academic research and community activities. In her role as the Co-Director of the Connecticut Emerging Infections Program at the Yale School of Public Health, she has championed the expansion of vaccine education and access. She regularly promotes the use of immunization registries to help assess vaccine coverage in urban communities and the expansion of immunization education initiatives to under-served populations. Her research examines the impacts racial, economic, educational, and gender gaps have on disease awareness and vaccine access.

Dr. Niccolai is actively involved with Connecticut's Childhood Vaccine Advisory Council (CVAC) and promotes immunization through speaking engagements with community groups, immunization partners, and medical providers. Dr. Niccolai also partners with the regional Immunization Action Plan (IAP) coordinators to discuss initiatives to increase immunization rates and works hard to educate parents and providers on the safety of vaccines and their importance on positive health outcomes.

Dr. Niccolai's commitment to immunization research and education makes her Connecticut's 2017 *CDC Childhood Immunization Champion*!